The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.90

Today's change+0.08 +0.48%
Updated February 27 4:04 PM EST. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.90

Today's change+0.08 +0.48%
Updated February 27 4:04 PM EST. Delayed by at least 15 minutes.

Boston Scientific Corp Hits New 52-week High

Boston Scientific Corp closed up Friday by (U.S.)$0.08 or 0.48% to (U.S.)$16.90 and setting a new 52-week high. Over the last five days, shares have gained 2.61% and 27.55% year to date. Shares have outperformed the S&P 500 by 13.57% during the last year.

Key company metrics

  • Open(U.S.) $16.83
  • Previous close(U.S.) $16.82
  • High(U.S.) $17.01
  • Low(U.S.) $16.75
  • Bid / Ask-- / --
  • YTD % change+27.55%
  • Volume11,291,042
  • Average volume (10-day)19,743,437
  • Average volume (1-month)15,366,950
  • Average volume (3-month)13,139,793
  • 52-week range(U.S.) $11.10 to (U.S.) $17.01
  • Beta1.04
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward18.66×
  • Forward PEG1.85×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.09
Updated February 27 4:04 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-1.61%

Boston Scientific Corp has a net profit margin of -1.61%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014
Revenue1,8871,8461,8731,774
Total other revenue--------
Total revenue1,8871,8461,8731,774
Gross profit1,3281,3051,3141,239
Total cost of revenue559541559535
Total operating expense2,3791,7821,9421,577
Selling / general / administrative752735737660
Research & development208212206191
Depreciation / amortization111109109109
Interest expense (income), net operating--------
Unusual expense (income)72416430642
Other operating expenses, total25212540
Operating income-49264-69197
Interest income (expense), net non-operating-55-54-53-54
Gain (loss) on sale of assets--------
Other--------
Income before tax-5543-104146
Income after tax-299434133
Income tax, total-255-40-10813
Net income-299434133
Total adjustments to net income--------
Net income before extra. items-299434133
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-299434133
Inc. avail. to common incl. extra. items-299434133
Diluted net income-299434135
Dilution adjustment0----2
Diluted weighted average shares1,3271,3481,3451,349
Diluted EPS excluding extraordinary itemsvalue per share-0.230.030.000.10
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.130.110.150.12